NASDAQ:VRNA Verona Pharma - VRNA Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Verona Pharma plc Please log in to your account or sign up in order to add this asset to your watchlist. $20.35 -0.28 (-1.36%) (As of 03/27/2023 12:00 AM ET) Add Compare Share Share Today's Range$20.32▼$21.1050-Day Range$18.06▼$23.6952-Week Range$3.41▼$26.44Volume347,699 shsAverage Volume500,259 shsMarket Capitalization$1.54 billionP/E RatioN/ADividend YieldN/APrice Target$29.33 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Verona Pharma MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside44.1% Upside$29.33 Price TargetShort InterestHealthy2.89% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.18Based on 4 Articles This WeekInsider TradingSelling Shares$2.79 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($0.90) to ($0.91) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.97 out of 5 starsMedical Sector404th out of 995 stocksPharmaceutical Preparations Industry185th out of 482 stocks 3.5 Analyst's Opinion Consensus RatingVerona Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $29.33, Verona Pharma has a forecasted upside of 44.1% from its current price of $20.35.Amount of Analyst CoverageVerona Pharma has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted2.89% of the float of Verona Pharma has been sold short.Short Interest Ratio / Days to CoverVerona Pharma has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Verona Pharma has recently increased by 3.97%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldVerona Pharma does not currently pay a dividend.Dividend GrowthVerona Pharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for VRNA. Previous Next 3.4 News and Social Media Coverage News SentimentVerona Pharma has a news sentiment score of 1.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Verona Pharma this week, compared to 2 articles on an average week.Search Interest10 people have searched for VRNA on MarketBeat in the last 30 days. This is an increase of 150% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Verona Pharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -60% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Verona Pharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,789,983.00 in company stock.Percentage Held by InsidersOnly 3.90% of the stock of Verona Pharma is held by insiders. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Verona Pharma are expected to decrease in the coming year, from ($0.90) to ($0.91) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Verona Pharma is -18.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Verona Pharma is -18.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVerona Pharma has a P/B Ratio of 6.67. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Verona Pharma (NASDAQ:VRNA) StockVerona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.Read More Receive VRNA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Verona Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address VRNA Stock News HeadlinesMarch 27, 2023 | seekingalpha.comVerona's Ensifentrine: A Promising Novel Treatment For COPD PatientsMarch 23, 2023 | americanbankingnews.comBTIG Research Boosts Verona Pharma (NASDAQ:VRNA) Price Target to $31.00March 28, 2023 | Stansberry Research (Ad)The gold catalyst we’ve waited forIf you thought the SVB meltdown was bad… watch out. Because even bigger red flag just appeared. This signal proves that a recession is likely right around the corner. It will take most by surprise. Stocks will crash. Millions will go jobless, and lose their homes. But there is ONE important step you should take today to make sure you come out the other side OK. March 22, 2023 | finance.yahoo.comVerona Pharma PLC American Depositary Share (VRNA) Stock Moves -0.46%: What You Should KnowMarch 13, 2023 | msn.com4 Analysts Have This to Say About Verona PharmaMarch 13, 2023 | markets.businessinsider.comH.C. Wainwright Reaffirms Their Buy Rating on Verona Pharma (VRNA)March 9, 2023 | finance.yahoo.comVerona Pharma plc (NASDAQ:VRNA) Q4 2022 Earnings Call TranscriptMarch 8, 2023 | bizjournals.comRaleigh drugmaker eyes regulatory push for COPD treatmentMarch 28, 2023 | Tradewins (Ad)Modern Day Options Trading For Beginners!These days it takes more than willpower to succeed on Wall Street and for new traders, even small mistakes can sink an account! With "Your Guide To Successful Options Trading" by expert Wendy Kirkland, you can avoid new trader pitfalls and learn to earn in this vicious market. March 7, 2023 | finanznachrichten.deVerona Pharma plc: Verona Pharma Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate UpdateMarch 7, 2023 | finance.yahoo.comVerona Pharma Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate UpdateMarch 6, 2023 | msn.comEarnings Preview For Verona PharmaMarch 1, 2023 | finance.yahoo.comVerona Pharma plc (NASDAQ:VRNA) is definitely on the radar of institutional investors who own 39% of the companyFebruary 23, 2023 | finance.yahoo.comVerona Pharma PLC American Depositary Share (VRNA) Gains But Lags Market: What You Should KnowFebruary 21, 2023 | finance.yahoo.comVerona Pharma to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate UpdateFebruary 15, 2023 | finance.yahoo.comVerona (VRNA) to Report Q4 Earnings: What's in the Cards?February 14, 2023 | finance.yahoo.comVerona Pharma PLC American Depositary Share (VRNA) Gains As Market Dips: What You Should KnowFebruary 1, 2023 | seekingalpha.comVerona: Second Successful Phase 3 Moves The Needle ForwardJanuary 17, 2023 | finance.yahoo.comVerona Pharma PLC American Depositary Share (VRNA) Dips More Than Broader Markets: What You Should KnowJanuary 10, 2023 | finance.yahoo.comVerona Pharma PLC American Depositary Share (VRNA) Stock Sinks As Market Gains: What You Should KnowDecember 30, 2022 | finance.yahoo.com4 Drug Stocks That More Than Doubled This YearDecember 20, 2022 | msn.comHot Stocks: TSLA sets another new 52-week low; FCEL drops on earnings; DLO, VRNA roseDecember 20, 2022 | msn.comBTIG Maintains Buy Rating for Verona Pharma: Here's What You Need To KnowDecember 20, 2022 | finance.yahoo.comVerona Pharma Stock Garners Investors' Attention After Successful COPD TrialDecember 20, 2022 | finance.yahoo.comTop-Notch Verona Pharma Scores A Win In COPD — And Hits A Four-Year HighDecember 20, 2022 | finance.yahoo.comRaleigh drugmaker's stock jumps on positive results for lung disease treatmentDecember 20, 2022 | finanznachrichten.deVerona Pharma plc: Verona Pharma Announces Ensifentrine Meets Primary and Key Secondary Endpoints in Phase 3 ENHANCE-1 Trial for COPDSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive VRNA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Verona Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address VRNA Company Calendar Last Earnings3/07/2023Today3/28/2023Next Earnings (Estimated)5/02/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:VRNA CUSIPN/A CIK1657312 Webwww.veronapharma.com Phone011-44-0-2032834200FaxN/AEmployees24Year FoundedN/APrice Target and Rating Average Stock Price Forecast$29.33 High Stock Price Forecast$32.00 Low Stock Price Forecast$27.00 Forecasted Upside/Downside+44.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($1.12) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-68,700,000.00 Net MarginsN/A Pretax Margin-14,944.98% Return on Equity-38.97% Return on Assets-32.01% Debt Debt-to-Equity Ratio0.04 Current Ratio12.77 Quick Ratio12.77 Sales & Book Value Annual Sales$460,000.00 Price / Sales3,345.36 Cash FlowN/A Price / Cash FlowN/A Book Value$3.05 per share Price / Book6.67Miscellaneous Outstanding Shares75,620,000Free Float72,674,000Market Cap$1.54 billion OptionableNot Optionable Beta0.13 Key ExecutivesDr. David S. Zaccardelli (Age 57)Pres, CEO & Exec. Director Comp: $627.27kMr. Mark W. Hahn (Age 59)Chief Financial Officer Comp: $639.08kDr. Kathleen A. Rickard (Age 64)Chief Medical Officer Comp: $562.38kMs. Claire Louise Poll L.C.S.W. (Age 55)B.A., B Juris, LLB, ASIA, Gen. Counsel Ms. Victoria StewartDirector of CommunicationsMr. Matthew CasbonVP of Sales, Marketing & TrainingMs. Ostra JewellSr. VP of HRDr. Peter Spargo (Age 60)Sr. VP of Chemistry Manufacturing & Controls Dr. Tara Rheault M.P.H. (Age 45)Ph.D., Sr. VP of R&D Ms. Nina ChurchExec. Director of Global Clinical Devel.More ExecutivesKey CompetitorsArvinasNASDAQ:ARVNSyndax PharmaceuticalsNASDAQ:SNDXCureVacNASDAQ:CVACMorphicNASDAQ:MORFChinook TherapeuticsNASDAQ:KDNYView All CompetitorsInsiders & InstitutionsVoya Investment Management LLCBought 21,380 shares on 2/28/2023Ownership: 0.028%Truist Financial CorpBought 11,600 shares on 2/17/2023Ownership: 0.015%Caligan Partners LPBought 183,064 shares on 2/16/2023Ownership: 0.242%Legal & General Group PlcBought 24,653 shares on 2/15/2023Ownership: 0.033%Belvedere Trading LLCBought 8,100 shares on 2/15/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions VRNA Stock - Frequently Asked Questions Should I buy or sell Verona Pharma stock right now? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Verona Pharma in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" VRNA shares. View VRNA analyst ratings or view top-rated stocks. What is Verona Pharma's stock price forecast for 2023? 6 equities research analysts have issued 12-month price objectives for Verona Pharma's stock. Their VRNA share price forecasts range from $27.00 to $32.00. On average, they anticipate the company's stock price to reach $29.33 in the next year. This suggests a possible upside of 44.1% from the stock's current price. View analysts price targets for VRNA or view top-rated stocks among Wall Street analysts. How have VRNA shares performed in 2023? Verona Pharma's stock was trading at $26.13 on January 1st, 2023. Since then, VRNA shares have decreased by 22.1% and is now trading at $20.35. View the best growth stocks for 2023 here. When is Verona Pharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 2nd 2023. View our VRNA earnings forecast. How were Verona Pharma's earnings last quarter? Verona Pharma plc (NASDAQ:VRNA) released its quarterly earnings data on Tuesday, March, 7th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.22) by $0.06. The business earned $0.46 million during the quarter. What ETFs hold Verona Pharma's stock? ETFs with the largest weight of Verona Pharma (NASDAQ:VRNA) stock in their portfolio include ALPS Medical Breakthroughs ETF (SBIO), Invesco Nasdaq Biotechnology ETF (IBBQ), ProShares Ultra Nasdaq Biotechnology (BIB) and iShares Biotechnology ETF (IBB). What other stocks do shareholders of Verona Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Verona Pharma investors own include Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Trevena (TRVN), Pfizer (PFE), Citius Pharmaceuticals (CTXR), electroCore (ECOR), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), VBI Vaccines (VBIV) and Vaxart (VXRT). When did Verona Pharma IPO? (VRNA) raised $61 million in an IPO on Thursday, April 27th 2017. The company issued 4,500,000 shares at $13.49 per share. Jefferies and Stifel acted as the underwriters for the IPO and Wedbush PacGrow and SunTrust Robinson Humphrey were co-managers. What is Verona Pharma's stock symbol? Verona Pharma trades on the NASDAQ under the ticker symbol "VRNA." Who are Verona Pharma's major shareholders? Verona Pharma's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include RA Capital Management L.P. (8.35%), Fairmount Funds Management LLC (3.80%), Frazier Life Sciences Management L.P. (3.72%), Jennison Associates LLC (1.36%), Samsara BioCapital LLC (0.92%) and Two Sigma Investments LP (0.69%). Insiders that own company stock include Anders Ullman, Claire Poll, David Zaccardelli, Kathleen A Rickard, Lisa Deschamps, Mark W Hahn, Mark W Hahn, Orbimed Advisors Llc and Patrick John Finn. View institutional ownership trends. How do I buy shares of Verona Pharma? Shares of VRNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Verona Pharma's stock price today? One share of VRNA stock can currently be purchased for approximately $20.35. How much money does Verona Pharma make? Verona Pharma (NASDAQ:VRNA) has a market capitalization of $1.54 billion and generates $460,000.00 in revenue each year. The company earns $-68,700,000.00 in net income (profit) each year or ($1.12) on an earnings per share basis. How can I contact Verona Pharma? Verona Pharma's mailing address is 3 MORE LONDON RIVERSIDE, LONDON X0, SE1 2RE. The official website for the company is www.veronapharma.com. The company can be reached via phone at 011-44-0-2032834200 or via email at verona@argotpartners.com. This page (NASDAQ:VRNA) was last updated on 3/28/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.